IMV News and Press, IMV Inc. From 03/18/20

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a c...

First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved durable clinical benefit lasting ≥ 6 months; including four partia...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will host a conference call & webcast to report topline results from DeCidE1, an ongoing Phase 2 study evaluating its lead comp...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that Albert Scardino will retire from the IMV Board of Directors effective February 28th, 2020. Mr. Scardino, 71, joined the board in 2011 and served a...

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

DPX-Survivac generated strong, sustained and functional survivin-specific T cell response in 80% of patients’ blood samples Clinical anti-tumor responses were correlated with increased infiltration of T cells into tumors following treatment with DPX-Survivac Antigen-specifi...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at the BIO CEO and Investor Conference on Monday, February 10, 2020 at 9:30 a.m. ET in New York, NY. A live webc...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that it will host a key opinion leader symposium on the role of survivin in cancer biology and DPX-Survivac’s potential as a targeted immunotherapeu...

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell responses and favorable safety profile observed in all seven subjects that achieved clinical benefit on treatment Top-line...